Afyren
AFYREN meets a growing need among businesses and industries to reduce the use of petroleum-based products in their production lines. It does this by producing biomolecules derived from non-food biomass, largely used in the sectors of cosmetics, flavors and fragrances, feed and food, and fine chemicals. This production of renewable carbon, within a circular economy, is achieved through worldwide patented fermentation technology resulting from 10 years of research. Afyren went public in October 2021 on the Euronext Growth market (ALAFY).
Sector
Industrial Biotech
Strategies
Industrial Biotech
Status
Live
Website
afyren.com
Related News
AFYREN begins new phase of industrial strategy as first plant AFYREN NEOXY achieves continuous production
AFYREN announces signing of new commercial contract with US nutraceutical maker
Afyren's fermentation lab reaches 2-million-hour-mark as it identifies new raw materials to fuel industrial expansion
Afyren provides business update on its Afyren Neoxy plant
AFYREN is ramping up its efforts to create a new path for organic waste recovery
Production operations at AFYREN NEOXY plant make significant progress, with first lots delivered
AFYREN chooses Thailand for its second biobased organic acids plant, entering a partnership project with Mitr Phol, a global leader in the sugar industry
AFYREN adds new hires to support growth in France and expansion abroad
AFYREN inaugurates its first factory, AFYREN NEOXY, a first-of-its-kind biorefinery
AFYREN announces the industrial commissioning of its AFYREN NEOXY plant and publishes its 2021 Full-Year Results
AFYREN lists on Euronext Growth Paris
Green chemistry on an industrial scale: AFYREN starts construction of its first factory
AFYREN appoints Stefan Borgas as Chairman of the Board
AFYREN and the AFTER-BIOCHEM European consortium obtain a funding of 20 million euros for the industrial production of new bio-based products
AFYREN and the SPI industrial projects fund, operated by Bpifrance, announce the creation of an industrial company, AFYREN NEOXY.
AFYREN secures over 60 million euros of financing to move into its industrial development phase
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.